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ABSTRACT 
Variants within the MMP3 (rs679620) and TIMP2 (rs4789932) genes have been 
associated with the risk of Achilles tendon pathology (ATP) in populations from South 
Africa and Australia. This study aimed to determine whether these variants were 
associated with the risk of ATP in British Caucasians. We recruited 118 cases with 
ATP, including a subset of 25 individuals with Achilles tendon rupture (RUP) and 131 
controls. DNA samples were isolated from saliva and genotyped using qPCR. For the 
TIMP2 rs4789932 variant we found a significant (p=0.038) difference in the genotype 
distribution frequency between males with ATP (CC, 39.4%; CT, 43.7%; TT, 16.9%) 
compared to male controls (CC, 20.7%; CT, 59.8%; TT, 19.5%). We also observed a 
difference in the TIMP2 rs4789932 genotype distribution between males with rupture 
compared to male controls (p=0.038). The MMP3 rs679620 GG genotype was found 
to be overrepresented in the Achilles tendon rupture (RUP) group (AA, 24.0%; AG, 
32.0%; GG, 44.0%) compared to controls (AA, 26.7%; AG, 54.2%; GG, 19.1%). In 
conclusion, the CT genotype of the TIMP2 rs4789932 variant was associated with 
lower risk of ATP in males. Furthermore, while we revealed differences for both 
variants in genotype distribution between the RUP and control groups, the sample 
size of the RUP group was small and confirmation would be required in additional 
cohorts. Finally, although both the TIMP2 rs4789932 and MMP3 rs679620 variants 
tentatively associated with ATP, there were differences in the direction of association 
compared to earlier work. 
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INTRODUCTION 
Achilles tendon pathology (ATP) is an umbrella term that refers to both Achilles 
tendinopathy (TEN) and Achilles tendon rupture (RUP).  ATP is a debilitating 
condition and most cases are related to overuse injury caused by chronic or acute 
exposure to repetitive micro-traumas (Kvist 1994). Several intrinsic and extrinsic risk 
factors for ATP have been reported, and an increasing number of association studies 
have demonstrated that genetic variants can predispose to the condition (Raleigh 
and Collins 2012).   
 
The extracellular matrix (ECM) within a tendon consists of collagen fibrils, 
proteoglycans, glycoproteins and glycosaminoglycans (Sharma and Maffulli 2005). In 
addition to structural proteins, non-structural proteins and enzymes contribute 
towards homeostasis by constantly remodelling the ECM (Magra and Maffulli 2005). 
MMP3 belongs to the family of metalloproteinases (MMPs) which are known for their 
role in controlling the ECM integrity by catalytically degrading structural proteins 
including laminin, fibronectin, and various types of collagen (Somerville et al. 2003; 
Birkedal-Hansen et al. 1993). MMP3 is known to stimulate the activity of other MMPs 
which eventually contribute towards the catalysis of other proteins within the ECM 
(Toth et al. 2003). However, MMP3 mRNA levels have been consistently shown to be 
lower in ATP samples when compared to the controls (Ireland et al. 2001; Alfredson 
et al. 2003). Tissue inhibitors of metalloproteases (TIMPs) are known for their role in 
inhibiting the activity of metalloproteinases by interacting with the MMP active site 
(Young et al. 2002). Although TIMP2 does not inhibit the activity of MMP3, it inhibits 
the activation of MMP2 which works in parallel with MMP3 to activate MMP9 (Toth et 
al. 2003). Therefore, by limiting the activity of MMP2, TIMP2 is considered to 
indirectly reduce the impact of MMP3 activity.  
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Recent work has shown that the rs679620 single nucleotide polymorphism (SNP) 
within the MMP3 gene and the rs478992 SNP within the TIMP2 gene were risk 
factors for ATP in a South African (Raleigh et al. 2009) and a combined South 
African and Australian cohort respectively (El Khoury et al. 2013). However, as 
genetic predisposition to multifactorial phenotypes is often population specific, we 
wished to ascertain whether these polymorphisms were also risk factors in a recently 
recruited British population. 
 
MATERIALS AND METHODS 
One hundred and eighteen (47 females and 71 males) British Caucasian participants 
diagnosed with Achilles tendon pathology (ATP) and 131 (49 females and 82 males) 
asymptomatic British Caucasian controls (CON) were recruited for this case-control 
genetic association study. All case participants were recruited from The County 
Clinic, Northampton, UK between 2011 and 2014.  A suitable control population of 
physically active individuals with regular exposure to lower limb exercise (minimum 2 
hrs/wk of high intensity exercise) and no history of Achilles tendon pathology,  were 
recruited from sports clubs within the East Midlands area. All participants gave 
written informed consent, according to the Declaration of Helsinki, and completed a 
medical and injury history questionnaire. All participants with ATP were diagnosed by 
the medical professional and co-author WJR based on the clinical criteria reported in 
previous studies (Mokone et al. 2005; September et al. 2009). For patients with 
tendon ruptures, the clinical diagnosis was corroborated in most cases (88.0%, n=22) 
by either imaging (60.0%, n=15) and/or surgical observation (52.0%, n=13). Our 
recruitment and experimental protocols were approved by the University of 
Northampton Research Ethics Committee. 
 
The ATP group consisted of 93 (39 females and 54 males) participants with chronic 
Achilles tendinopathy (TEN), and 25 (8 females and 17 males) participants with 
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Achilles tendon rupture (RUP). Patients with chronic Achilles tendinopathy (TEN) 
were diagnosed as suffering from either non-insertional (n=51, 54.8%), insertional 
tendinopathy (n=28, 30.1%), or both (n=14, 15.0%). Achilles ruptures were 
categorised as full or partial ruptures. For the purpose of analysis, participants 
diagnosed with Achilles tendinopathy who later sustained an Achilles rupture (n=12), 
were included in the RUP group. At the time of recruitment participants in the ATP 
group were generally healthy with the exception of 18 (15.2%) individuals who were 
on medication for different cardiovascular conditions. We also report that 34 (28.8%) 
ATP cases reported a history of tendinopathy in a tendon other than the Achilles 
tendon, 46 (38.9%) reported a history of ligament injury. 
 
Saliva samples were collected from each participant using OrageneTM OG-500 tubes 
(DNA Genotek, Ontario, Canada).  DNA was extracted according to the 
manufacturer’s protocol using a PT-L2P lysis solution. DNA samples were genotyped 
for the MMP3 rs679620 and TIMP2 rs4789932 gene variants using fluorescence-
based TaqMan® Custom SNP Genotyping Assays (Applied Biosystems, Foster City, 
CA, USA). The qPCR reactions contained probes and primers and PCR mastermix 
containing AmpliTaq DNA Polymerase Gold (Applied Biosystems, Foster City, CA, 
USA) in a total reaction volume of 6 μL. PCR was performed on an Applied 
Biosystems StepOnePlusTM real-time PCR system (Applied Biosystems, Foster City, 
CA, USA). Genotypes were determined following end point fluorescence analysis 
using Applied Biosystems StepOnePlusTM real-time PCR software Version 2.1. Rox 
was used as a passive reference and each PCR run included a number of both 
positive (sample repeats) and negative (water) controls.  
 
Data were analysed using SPSS Version 20 (IBM SPSS, IBM Corp, Somers, NY, 
USA) statistical program. A chi-squared (2) analysis was used to determine whether 
significant genotype and/or allele distribution differences existed between CON and 
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ATP groups. An independent t-test was used to establish if any significant differences 
existed between the participants’ characteristics of the ATP and CON groups and an 
analysis of variance was used to identify differences in participants’ characteristics 
when grouped into genotypes. In all analyses significance was accepted when 
p<0.05. No adjustment for multiple testing was made due to  the rationale described 
in our previous studies (Posthumus et al. 2011). Hardy-Weinberg equilibrium was 
determined using Michael H. Court's (2005–2008) online calculator (www.tufts.edu). 
We used Quanto software (version 1.2) for power calculations and found that, for our 
entire cohort, the sample size was sufficient to detect associations with 
approximately 80% power at the p<0.05 level with odds ratios of 2.2 and above. 
 
RESULTS 
The CON and ATP groups were matched for age, height, weight, and body mass 
index (BMI). However, when the data was stratified according to gender, we found a 
difference in height (p=0.023) between the males ATP and CON groups. Males in the 
CON group were taller than those in the ATP group (table 1). However, height was 
not a confounding variable in our analysis as genotypes at both of the loci tested did 
not associate with height. 
 
The allele and genotype distribution frequencies for the MMP3 and TIMP2 variants 
are shown in table 2 and 3 respectively. We found a significantly (p=0.021) different 
genotype distribution frequency of the MMP3 rs679620 variant between the CON 
(AA, 26.7%; AG, 54.2%; GG, 19.1%) and the RUP (AA, 24.0%; AG, 32.0%; GG, 
44.0%) groups. The GG genotype was significantly over-represented among the 
RUP group (p=0.009; OR=3.33; 95% CI 1.35 – 8.21), whereas the AG genotype was 
significantly over-represented among the CON group (p=0.046; OR=2.51; 95% CI 
1.01 – 6.23). However, the number of patients who presented with ruptures was 
small and, as such, this result would require confirmation in additional cohorts. In 
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addition, we found a significantly different (p=0.038) genotype distribution for the 
TIMP2 rs4789932 variant in male participants between the CON (CC, 20.7%; CT, 
59.8%; TT, 19.5%) and ATP (CC, 39.4%; CT, 43.7%; TT, 16.9%) groups. The CT 
genotype was significantly over-represented within the male CON group (p=0.004; 
OR=2.75; 95% CI 1.38 – 5.44), whereas the CC genotype was over represented in 
the ATP group (p=0.012; OR=2.49; 95% CI 1.22 – 5.09). A similar trend in 
distribution was found between the male CON and RUP groups (p=0.038). 
 
There was no significant genotypic distribution difference for the TIMP2 rs4789932 
variant between the CON and ATP groups within female participants (p=0.639), or in 
the combined male plus female group (p=0.364). Furthermore, we report no 
genotypic distribution differences for the MMP3 rs679620 variant between the CON 
and ATP groups (p=0.413), or between the CON and the TEN group (p=0.564) (table 
2). We also report no allelic distribution difference for either gene variants between 
the CON and ATP groups (Table 2 and 3). All the genotype distribution groups 
included in this study were in Hardy-Weinberg equilibrium (HWE). 
 
DISCUSSION 
We have primarily found a significant association (p=0.021) between the MMP3 
rs679620 variant and Achilles tendon rupture, with the GG genotype being over 
represented in the RUP group compared to the CON group. In an earlier study we 
found that the GG genotype was a risk factor for Achilles tendinopathy but not 
Achilles tendon rupture in South Africans Caucasians (Raleigh et al. 2009). The G 
allele of the rs679620 locus is known to increase MMP3 expression (Foster et al. 
2012), as it is in high linkage disequilibrium (LD) with the 5A allele of the rs3025058 
variant (Chen et al. 2012). The 5A allele has been reported to up-regulate MMP3 
mRNA levels (Ye 2006). Accordingly, over-expression of the MMP3 gene could 
increase the risk of tendon degeneration since MMP3 protein plays a role in the 
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breakdown of ECM substrates such as proteoglycan, decorin, and laminin (Birkedal-
Hansen et al. 1993). Therefore, an accelerated or excessive MMP3 mediated 
destruction of some of these ECM components might predispose to tendon rupture. 
 
We have also shown that the TIMP2 rs4789932 variant is associated with the risk of 
ATP in British males. Specifically, the CC genotype was over represented in the ATP 
and RUP groups compared to an over representation of the CT genotype in the CON 
group. This finding differs with an earlier study in which the CC genotype was over 
represented among controls and the CT genotype associated with ATP cases in a 
combined Australian and South African Caucasian population (El Khoury et al. 2013). 
However, although the direction of the association found in this study (CC genotype 
as risk factor) was opposite to that reported in the earlier work (CC genotype as 
protective factor), the data might indicate that a complex mechanism underlies the 
involvement of this locus in the predisposition to ATP.  Indeed it has recently been 
noted that reverse effects in genetic association studies may reveal additional 
information about a susceptibility locus that was previously unknown. For example, 
minor alterations in allele frequency between populations, differences in interacting 
loci, gene-gene, and gene-environment interactions may all contribute to a reverse 
effect, even in populations that are of the same ethnicity but drawn from different 
geographic locations (Greene et al. 2009). The reversal effect could also be due to a 
difference in LD between the associated and the causative variant between different 
populations of the same ethnicity (Ferreiros-Vidal et al. 2007). Furthermore, it is 
possible that genes in individuals from different regions undergo local adaptation 
following geographical and environmental isolation (Tiffin & Ross-Ibarra 2014; Sexton 
et al. 2014). This can sometimes be explained by the concept of conditional neutrality 
where an allele can be neutral in certain locations and risk related in a completely 
different setting (Fournier-Level et al. 2011). Such effects have been reported in 
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systemic lupus erythematosus, where the PD1.3 A allele of the PDCD1 gene 
associates with risk related characteristics in some European Caucasian populations 
but it has protective characteristics in others (Ferreiros-Vidal et al. 2007; Ferreiros-
Vidal et al. 2004). With relevance to this, the association described in this study was 
found in British Caucasian males whereas our previous work was conducted in a 
Caucasian population of both genders recruited from Australia and South Africa (El 
Khoury et al. 2013).   
 
At present we cannot specifically explain why the TIMP2 rs4789932 variant 
influences the risk of ATP or Achilles tendon rupture but it is noteworthy that a 
number of studies have found that TIMP2 expression is altered in tendon tissue 
under a variety of conditions. For example, Jones et al. (2006) have shown that 
TIMP2 expression is reduced in human degenerate Achilles tendon compared to 
healthy tissue. Furthermore ageing was found to significantly reduce the expression 
level of TIMP2 in rabbit patellar tendons (Thornton et al. 2013). Hence, a reduction in 
TIMP2 levels might contribute to tendon degradation since lower levels have been 
speculated to disrupt the TIMP/MMP balance and adversely alter ECM homeostasis 
(Pasternak et al. 2010). Interestingly, TIMP2 expression in human ruptured Achilles 
tendon has been found to increase relative to non-rupture tendon samples (Karousou 
et al. 2008) and a study in rodents showed that overuse of the supraspinatus tendon 
was accompanied by an intial decrease in TIMP2 levels followed by a subsequent 
rise (Attia et al. 2013). This latter observation may well explain the observed 
decrease in TIMP2 during tendon degradation which apparently takes place at the 
pre-rupture stage (Jones et al. 2006). Consequently, a rupture may occur at an 
advanced stage of tendinopathy and thus might be accompanied by an increase in 
TIMP2 levels.  
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In summary, this study follows the work previously conducted in South African and 
Australian Caucasian populations (Raleigh et al. 2009; El Khoury et al. 2013). These 
earlier studies showed that both the MMP3 rs679620 and the TIMP2 rs4789932 
variants associated with ATP in the South African cohort (MMP3 rs679620 variant) 
(Raleigh et al. 2009) and when both populations were combined (TIMP2 rs4789932 
variant) (El Khoury et al. 2013). Our present study in British Caucasians reveals that 
the association of the TIMP2 rs4789932 variant with ATP and Achilles tendon rupture 
is only apparent in males.  Furthermore, we found that it was carriage of the CC 
genotype that inferred risk as opposed to the CT genotype in the combined South 
African and Australian cohorts which inferred risk of ATP but not Achilles tendon 
rupture. Finally, for the MMP3 rs679620 variant, we found a tentative association 
between the GG genotype with Achilles tendon rupture but not with tendinopathy per 
se.  
 
To conclude, although this study did not directly replicate the direction of associations 
we found in earlier work (Raleigh et al. 2009; El Khoury et al. 2013) it was confirmed 
that the same loci seemed to modify the risk of Achilles tendon pathology or rupture 
in some way. This may well reflect the fact that the current work was conducted in a 
population recruited from a different geographic region compared to our earlier work. 
In terms of limitations, we must treat these data as tentative findings and remember 
that confidence in our data would be greater if the work was repeated in a larger 
cohort. A specific limitation was that sample size was reduced when we conducted 
gender specific analysis and when we stratified the ATP cohort into the separate sub 
groups (tendinopathy or rupture). This would result in a reduction in statistical power.  
Finally, these findings suggest that the risk of ATP phenotypes, associated with the 
loci investigated, are modified by both gender and geographical location. 
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Tables 
Table 1. General biological characteristics of the British Achilles tendon pathology (ATP) group and the asymptomatic control (CON) group, as well as the gender sub-
groupings 
          Female     Males   
  
CON 
(n=131) 
ATP 
(n=118) 
P-value 
  
CON 
(n=49) 
ATP 
(n=47) 
P-value 
  
CON 
(n=82) 
ATP 
(n=71) 
P-value 
Age 
41.7 ± 
11.6 (124) 
43.7 ± 
13.8 (117) 
0.225 
 
44.3 ± 
14.4 (48) 
43.3 ± 
13.2 (46) 
0.691 
 
40.0 ± 
11.5 (76) 
43.9 ± 
14.4 (71) 
0.071 
Gender 
(Male) 
62.6 (82) 60.2 (71) 0.695 
        
Height 
(cm) 
174.9 ± 
10.4 (123) 
172.9 ± 
9.2 (115) 
0.122 
 
165.5 ± 
7.1 (48) 
165.0 ± 
5.6 (46) 
0.731 
 
180.9 ± 
7.2 (75) 
178.2 ± 
7.1 (69) 
0.023 
Weight 
(kg) 
80.1 ± 
19.6 (124) 
78.7 ± 
15.6 (86) 
0.544 
 
63.7 ± 
10.9 (48) 
67.6 ± 
11.0 (35) 
0.111 
 
90.6 ± 
16.4 (76) 
86.3 ± 
13.7 (51) 
0.126 
BMI 
(kg/m
2
) 
25.9 ± 4.5 
(123) 
26.3 ± 4.1 
(86) 
0.543   
23.2 ± 3.5 
(48) 
24.9 ± 4.7 
(35) 
0.061   
27.6 ± 4.4 
(75) 
27.2 ± 3.3 
(51) 
0.558 
 
Values are expressed as mean ± SD or a frequency (%). The total number of participants (n). The maximum number (n) of participants in each category is also indicated at 
the top of each column. 
a
 age of the ATP, TEN, and RUP groups is at the age of initial injury, while the age of the CON groups is at the age of recruitment.   
b 
weight of the ATP, TEN, and RUP groups at the time of initial injury, while the weight of the CON groups is at the time of recruitment 
cm, centimetres; kg, kilograms; m, meters 
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Table 2. The genotype and allele frequency distribution of MMP3 rs679620 variant within the British control (CON) and Achilles tendon pathology (ATP) groups, as well as the 
chronic Achilles tendinopathy (TEN) and Achilles tendon rupture (RUP) sub-groups. 
       
Female 
 
Male 
  CON ATP   TEN RUP   CON ATP   TEN RUP   CON ATP   TEN RUP 
MMP3 
rs679620 
n=131 n=118 
 
n=93 n=25 
 
n=49 n=47 
 
n=39 n=8 
 
n=82 n=71 
 
n=54 n=17 
 
AA 
 
26.7 
(35) 
31.4 
(37)  
33.3 
(31) 
24.0 
(6)  
22.6 
(12) 
31.9 
(15)  
33.3 
(13) 
25.0 
(2)  
28.0 
(23) 
31.0 
(22)  
33.3 
(18) 
23.5 
(4) 
 
AG 
 
54.2 
(71) 
45.8 
(54)  
49.5 
(46) 
32.0 
(8)  
61.2 
(30) 
46.8 
(22)  
48.7 
(19) 
37.5 
(3)  
50.0 
(41) 
45.1 
(32)  
50.0 
(27) 
29.4 
(5) 
 
GG 
 
19.1 
(25) 
22.9 
(27)  
17.2 
(16) 
44.0 
(11)  
14.3 (7) 
21.3 
(10)  
17.9 
(7) 
37.5 
(3)  
22.0 
(18) 
23.9 
(17)  
16.7 
(9) 
47.1 
(8) 
 
P Value 
 
0.413a 
 
0.564b 0.021c 
 
0.358a 
 
0.499b 0.248c 
 
0.831a 
 
0.684b 0.122c 
 
HWE 
 
0.301 0.396 
 
0.879 0.056 
 
0.097 0.716 
 
0.990 0.500 
 
0.973 0.428 
 
0.834 0.120 
                  
 
G allele 
 
46.2 
(121) 
45.8 
(108)  
41.9 
(78) 
60.0 
(30)  
44.9 
(44) 
44.7 
(42)  
42.3 
(33) 
56.3 
(9)  
47.0 
(77) 
46.5 
(66)  
41.7 
(45) 
61.8 
(21) 
 
P Value 
 
0.925a 
 
0.373b 0.073c 
 
0.976a 
 
0.731b 0.399c 
 
0.934a 
 
0.391b 0.116c 
 
Values are expressed as a frequency with the number of participants (n) in parentheses. 
a 
CON vs ATP 
b
 CON vs TEN 
c
 CON vs RUP
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Table 3 The genotype and allele frequency distribution of TIMP2 rs4789932 variant within the British control (CON) and Achilles tendon pathology (ATP) groups, as well as 
the chronic Achilles tendinopathy (TEN) and Achilles tendon rupture (RUP) sub-groups 
       
Female 
 
Male 
  CON ATP   TEN RUP   CON ATP   TEN RUP   CON ATP   TEN RUP 
TIMP2 
rs4789932 
n=131 n=118 
 
n=93 n=25 
 
n=49 n=47 
 
n=39 n=8 
 
n=82 n=71 
 
n=54 n=17 
 
CC 
 
26.7 
(35) 
34.7 
(41)  
34.4 
(32) 
36.0 
(9)  
36.7 
(18) 
27.7 
(13)  
30.8 
(12) 
12.5 
(1)  
20.7 
(17) 
39.4 
(28)  
37.0 
(20) 
47.1 
(8) 
 
CT 
 
54.2 
(71) 
46.6 
(55)  
48.4 
(45) 
40.0 
(10)  
44.9 
(22) 
51.1 
(24)  
48.7 
(19) 
62.5 
(5)  
59.8 
(49) 
43.7 
(31)  
48.1 
(26) 
29.4 
(5) 
 
TT 
 
19.1 
(25) 
18.6 
(22)  
17.2 
(16) 
24.0 
(6)  
18.4 (9) 
21.3 
(10)  
20.5 
(8) 
25.0 
(2)  
19.5 
(16) 
16.9 
(12)  
14.8 
(8) 
23.5 
(4) 
 
P Value 
 
0.364a 
 
0.464b 0.425c 
 
0.636a 
 
0.841b 0.525c 
 
0.038a 
 
0.112b 0.038c 
 
HWE 
 
0.301 0.640 
 
0.979 0.346 
 
0.621 0.861 
 
0.924 0.445 
 
0.077 0.500 
 
0.924 0.120 
               
    
T allele 
 
46.2 
(121) 
41.9 
(99)  
41.4 
(77) 
44.0 
(22)  
40.8 
(40) 
46.8 
(44)  
44.9 
(35) 
56.3 
(9)  
49.4 
(81) 
38.7 
(55) 
 
38.9 
(42) 
38.2 
(13) 
 
P Value 
 
0.342a 
 
0.315b 0.776c 
 
0.403a 
 
0.589b 0.248c 
 
0.061a 
 
0.087b 0.236c 
Values are expressed as a frequency with the number of participants (n) in parentheses. 
a 
CON vs ATP 
b
 CON vs TEN 
c
 CON vs RUP
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Abbreviations 
ATP:   Achilles tendon pathology 
ECM:  Extra cellular Matrix 
MMP:  Matrix metalloproteinase 
RUP:  Rupture 
TEN:  Tendinopathy 
TIMP2: Tissue inhibitors of metalloproteinases 
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Highlights 
 
 MMP3 and TIMP2 gene variants associate with Achilles tendon pathology phenotypes. 
 
 Males carrying a TIMP2 genetic variant are more at risk than females.  
 
 Variability within MMP3 and TIMP2 genes might interact with geographic location to modify risk. 
